Tesabio.ai Appoints World-Class Scientific Advisory Board

Tesabio.ai, the AI-first therapeutics company restoring microRNA network balance in complex diseases, announced the formal incorporation of its Scientific Advisory Board (SAB). The SAB brings together leaders in RNA biology, single-cell and spatial omics, and translational genomics to guide Tesabio’s discovery roadmap and partnerships.

The inaugural SAB members are:

• Prof. Frank J. Slack — Harvard Medical School

• Dr. Charles A. Vanderburg — Broad Institute of MIT & Harvard

• Prof. Christopher Mason — Weill Cornell Medicine

“This SAB unites foundational expertise in microRNA biology with state-of-the-art genomics and systems medicine,” said Afshin Beheshti, PhD, co-founder and CSO of Tesabio.ai. “Their guidance strengthens our ability to translate AI-driven insights into small molecules that rebalance dysregulated microRNA networks, a mechanism with broad relevance across oncology, hematology, and neurodegeneration. With this team, we’ll accelerate rigorous target validation, refine our disease-prioritization strategy, and build high-impact collaborations spanning academia and industry.”